Chief Medical Officer · Sionna Therapeutics, Inc. (SION)

Charlotte McKee

FY2024 is the first fiscal year CompBrief holds for Charlotte McKee as a named executive officer of Sionna Therapeutics; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2024

$1,283,240

Salary $449,946Stock awards $0

3rd of 3 named executive officers at Sionna Therapeutics by FY2024 total.

3 named officers on file for Sionna Therapeutics, FY2024

Charlotte McKee’s pay file — $29

  • 1 fiscal year of pay, line by line

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Sionna Therapeutics’s whole pay program stands against its peers

  • Sionna Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on SION→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 29, 2025 (DEF 14A).

Free

Get Charlotte McKee’s full pay file as a PDF — free

More than this page: up to 10 years of Charlotte’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Charlotte McKee compensation by year

Sionna Therapeutics Summary Compensation Table · the one fiscal year held
In US dollars, as Sionna Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2024
Salary$449,946
Bonus$0
Stock awards$0
Option awards$635,318
Non-equity incentive$197,976
Pension and deferred compensation$0
All other$0
Total$1,283,240

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Sionna Therapeutics, Inc. DEF 14A filed April 29, 2025, accession 0001193125-25-101830, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Sionna Therapeutics, Inc. filed document, accession 0001193125-25-101830. Every figure is read from that document and cited to the page and table it appears in. Filed April 29, 2025.

Equity holdings

unvested awards at FY2024 year-end
TypeUnvested unitsValue at year-endExercise price
RSU18,943$195,681—
Option31,215—$6.11
Option115,266—$6.11

Per the Outstanding Equity Awards at Fiscal Year-End table in Sionna Therapeutics, Inc.'s FY2024 proxy; value at the fiscal year-end close, as the company printed it.

Sionna Therapeutics’s named executive officers, FY2024

as the company reported each
Named executive officerRoleFY2024 total
Michael CloonanChief Executive Officer$3,726,785
Elena RidloffChief Financial Officer and Head of Corporate Development$1,300,647
Charlotte McKee · this pageChief Medical Officer$1,283,240

The full Sionna Therapeutics compensation record

free company brief

This page is one person within Sionna Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Sionna Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Charlotte McKee's compensation dossier · One-time report. No refunds.